Signs of new growth in obesity treatment options are appearing at ObesityWeek 2014 in Boston this week. Novo Nordisk presented a sweeping scope of results on Tuesday from clinical trials with its drug, liraglutide, which is awaiting final approval from FDA. Researchers are presenting new data for other obesity treatments — lorcaserin, bupropion/naltrexone, and phenteramine/topiramate — that […]

